We appointed EverEdge to provide an intangible asset analysis and valuation. The depth of EverEdge’s analysis of our business, as well as the sector and geographies we are focused on, was impressive. The report highlighted and contextualized the strength of our intangible asset portfolio and how it contributes to the overall valuation of our business.

The process we went through with EverEdge helped us to refine our overarching business strategy, while the robust valuation report will now help us put our plans into action. This has built up our confidence in identifying, managing and securing our intangible assets which has become pivotal to Sierra’s future.

EverEdge crystalised the value of our years of investment in developing our own software suite and the building of our customer base - that we knew was there but not what it was worth. They did this by putting a clear value on these assets as a result of an extraordinarily deep analysis supported by market conditions and factors.

CEO, International IT company

We engaged EverEdge to provide us with a specialist valuation that reflected the true value of our business and the intangible assets we had developed through many years of R&D. EverEdge’s valuation will be a critical tool as we look to grow our business and seek further investment.

We have had a long relationship with EverEdge, as its team helped us develop a strategy to build value in our portfolio of intangible assets. When EverEdge was appointed to advise Swisslog Healthcare on the sale of TransCar, its team was able to immediately identify the synergies with our business and the strategic value we could add to these assets if we acquired them. This transaction made sense for both OTSAW and TransCar and will allow both companies to focus on driving growth and margins in our core business’ by delivering innovative solutions and great service to our customers.

As a Biotech, our value is not in physical assets but in the intangible assets we generate through our R&D. As intangible assets traditionally sits off-balance sheet, existing financial reports do not provide investors with the tools to evaluate/compare our business with alternative Biotech investments. Working with EverEdge has helped us to identify and value our intangible assets, which in turn has enabled us to articulate the true value of our Company more effectively to our existing and potential investors.

The EverEdge team brought perspective, context and rigour to the table. This resulted in a valuation report of great value and utility.